Shyam Masrani

Shyam is a Partner at Medicxi. Prior to joining Medicxi, Shyam founded two early-stage biotechnology companies (Shyden Biotechnology and Cleavr Therapeutics). He led Medicxi's investment in Merus (NASDAQ:MRUS) and ProfoundBio (acquired by Genmab) and currently serves on the boards of a number of portfolio companies, including T-Cypher Bio, My-T Bio, Acera Therapeutics and Petalion Therapeutics.

Shyam obtained a BSc in Biochemistry and a Masters in Translational Medicine from Imperial College London.